Literature DB >> 16352795

Insulin, glucose, insulin resistance, and pancreatic cancer in male smokers.

Rachael Z Stolzenberg-Solomon1, Barry I Graubard, Suresh Chari, Paul Limburg, Philip R Taylor, Jarmo Virtamo, Demetrius Albanes.   

Abstract

CONTEXT: Obesity, diabetes mellitus, and glucose intolerance have been associated with increased pancreatic cancer risk; however, prediagnostic serum insulin concentration has not been evaluated as a predictor of this malignancy.
OBJECTIVE: To investigate whether prediagnostic fasting glucose and insulin concentrations and insulin resistance are associated with subsequent incidence of exocrine pancreatic cancer in a cohort of male smokers. DESIGN, SETTING, AND PARTICIPANTS: A case-cohort prospective study within the Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study (1985-1988) cohort of 29,133 male Finnish smokers ages 50 to 69 years. The study included 400 randomly sampled subcohort control participants and 169 incident pancreatic cancer cases that occurred after the fifth year of follow-up. All participants were followed up through December 2001 (up to 16.7 years of follow-up). MAIN OUTCOME MEASURES: Incident exocrine pancreatic cancer identified from the Finnish Cancer Registry.
RESULTS: After adjusting for age, smoking, and body mass index, higher baseline fasting serum concentrations of glucose, insulin, and insulin resistance were positively associated with pancreatic cancer. The presence of biochemically defined diabetes mellitus (glucose, > or =126 mg/dL [> or =6.99 mmol/L]) and insulin concentration in the highest vs lowest quartile both showed a significant 2-fold increased risk (hazard ratio [HR], 2.13; 95% confidence interval [CI], 1.04-4.35; and HR, 2.01; 95% CI, 1.03-3.93; respectively). There were significant interactions for all the biomarker exposures by follow-up time, such that the positive associations were stronger among the cases that occurred more than 10 years after baseline (highest vs lowest quartile: glucose, HR, 2.16; 95% CI, 1.05-4.42; P for trend = .02; insulin, HR, 2.90; 95% CI, 1.22-6.92; P for trend = .005; and insulin resistance, HR, 2.71; 95% CI, 1.19-6.18; P for trend = .006).
CONCLUSIONS: These results support the hypothesis that exposure to higher insulin concentrations and insulin resistance predicts the risk of exocrine pancreatic cancer.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16352795     DOI: 10.1001/jama.294.22.2872

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  158 in total

Review 1.  Vitamin D and Gastrointestinal Cancers: A Narrative Review.

Authors:  Hemant Goyal; Abhilash Perisetti; M Rubayat Rahman; Avi Levin; Giuseppe Lippi
Journal:  Dig Dis Sci       Date:  2018-12-03       Impact factor: 3.199

2.  Available carbohydrates, glycemic load, and pancreatic cancer: is there a link?

Authors:  Cari L Meinhold; Kevin W Dodd; Li Jiao; Andrew Flood; James M Shikany; Jeanine M Genkinger; Richard B Hayes; Rachael Z Stolzenberg-Solomon
Journal:  Am J Epidemiol       Date:  2010-05-07       Impact factor: 4.897

Review 3.  Review of screening for pancreatic cancer in high risk individuals.

Authors:  Alina Stoita; Ian D Penman; David B Williams
Journal:  World J Gastroenterol       Date:  2011-05-21       Impact factor: 5.742

Review 4.  Is dietary fat, vitamin D, or folate associated with pancreatic cancer?

Authors:  G V Sanchez; S J Weinstein; R Z Stolzenberg-Solomon
Journal:  Mol Carcinog       Date:  2012-01       Impact factor: 4.784

5.  Diabetes and pancreatic cancer.

Authors:  Donghui Li
Journal:  Mol Carcinog       Date:  2012-01       Impact factor: 4.784

6.  The relationship between glucose metabolism disorders and malignant thyroid disease.

Authors:  Ayse Ocak Duran; Cüneyd Anil; Alptekin Gursoy; Aslı Nar; Ozden Altundag; Neslihan Bascil Tutuncu
Journal:  Int J Clin Oncol       Date:  2012-06-30       Impact factor: 3.402

Review 7.  Cancer risk associated with use of metformin and sulfonylurea in type 2 diabetes: a meta-analysis.

Authors:  Davide Soranna; Lorenza Scotti; Antonella Zambon; Cristina Bosetti; Guido Grassi; Alberico Catapano; Carlo La Vecchia; Giuseppe Mancia; Giovanni Corrao
Journal:  Oncologist       Date:  2012-05-29

8.  Associations of obesity and circulating insulin and glucose with breast cancer risk: a Mendelian randomization analysis.

Authors:  Xiang Shu; Lang Wu; Nikhil K Khankari; Xiao-Ou Shu; Thomas J Wang; Kyriaki Michailidou; Manjeet K Bolla; Qin Wang; Joe Dennis; Roger L Milne; Marjanka K Schmidt; Paul D P Pharoah; Irene L Andrulis; David J Hunter; Jacques Simard; Douglas F Easton; Wei Zheng
Journal:  Int J Epidemiol       Date:  2019-06-01       Impact factor: 7.196

Review 9.  The Role of Nutraceuticals in Pancreatic Cancer Prevention and Therapy: Targeting Cellular Signaling, MicroRNAs, and Epigenome.

Authors:  Yiwei Li; Vay Liang W Go; Fazlul H Sarkar
Journal:  Pancreas       Date:  2015-01       Impact factor: 3.327

10.  Higher Glucose and Insulin Levels Are Associated with Risk of Liver Cancer and Chronic Liver Disease Mortality among Men without a History of Diabetes.

Authors:  Erikka Loftfield; Neal D Freedman; Gabriel Y Lai; Stephanie J Weinstein; Katherine A McGlynn; Philip R Taylor; Satu Männistö; Demetrius Albanes; Rachael Z Stolzenberg-Solomon
Journal:  Cancer Prev Res (Phila)       Date:  2016-08-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.